Hohenleitner Susan sold $6K of ARDX

Hohenleitner Susan (Chief Financial Officer) sold 1,558 shares of ARDELYX, INC. (ARDX) at $3.86 on 2026-08-21.

Original reporting
SEC EDGAR · Hohenleitner Susan
Published Aug 25, 2026, 11:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 25, 2026, 11:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The CFO's modest sale is unlikely to affect ARDX's stock price but adds to the transparency of insider activity.

02

Market read

Routine insider sale with minimal market impact.

03

What to watch

Potential upcoming compensation adjustments or tax planning.

Relevance 3/10Novelty 4/10Timing: filing date 2026-08-25

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

CFO Susan Hohenleitner sold 1,558 shares for $6,009, a routine insider sale disclosed via Form 4.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is small relative to total holdings and market cap; typical for CFOs.

Market effects

None

None

None

Counterpoint

Even small insider sales can precede larger off‑loadings; monitor future filings.

Key entities

  • Susan Hohenleitner

    Chief Financial Officer of ArdeLynx, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ARDXMed

Ardelyx (ARDX) Q3 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q3 2026 revenue of $125.5M, up 19% YoY. IBSRELA revenue grew 23% to $96.3M, while XPHOZAH revenue rose 7% to $29.2M. The company reaffirmed its full-year guidance and expects profitability in 2027. Ardelyx has $285.3M in cash and is advancing its ACCEL Phase III trial for chronic idiopathic constipation.

$ARDXLow

Ardelyx Inc (ARDX) (Q3 2026) Earnings Call Highlights: Revenue Climbs 19% as IBSRELA Shines

Ardelyx Inc (ARDX) reported a 19% revenue increase in Q3 2026, driven by its IBSRELA drug. CEO Michael Raab and CFO Sue Hohenleitner addressed prescription trends, payer negotiations, and the company's IBSRELA Pharmacy Network (IPN). They reaffirmed guidance, citing strong fundamentals and positive early indicators from a DTC campaign. The company also discussed its Phase 3 ACCEL trial for CIC and inventory dynamics for XPHOZAH.

$ARDXMedAI 8/10

What Ardelyx (ARDX) Said on Its Q3 Earnings Call

Ardelyx (ARDX) reported Q3 revenue of $29.2M for XPHOZAH, up 7% YoY. Paid prescriptions rose 22%, but demand was offset by customer buying patterns. The company maintained its full-year revenue outlook of $110M-$120M. Ardelyx also launched a direct-to-consumer ad campaign for IBSRELA, with 91% of patients expressing interest. R&D expenses increased to $25.2M, and the company reported a net loss of $700K. Ardelyx expects to reach profitability in 2027, with a gross profit margin exceeding 95%.